1. EGFL7 affected tumor growth and reduced overall survival
EGFL7 affected tumor growth and reduced overall survival ASchematic presentation of intracranial tumor implantation.BOverexpression of human EGFL7 (hE7) or murine EGFL7 (mE7) increased tumor growth (n = 9; one‐way ANOVA).CImmunocompetent mice bearing GL261 tumors. Representative MRI images confirmed tumor implantation in all experimental groups (left). Kaplan–Meier curves revealed decreased survival of mice bearing EGFL7‐expressing tumors (right; 34 days (control) vs. 29.5 days (hE7) vs. 31.5 days (mE7); n = 8; log‐rank test).DImmunodeficient mice bearing U87 tumors. Representative magnetic resonance images confirmed tumor implantation in all experimental groups (left). Kaplan–Meier curves revealed decreased survival of mice bearing EGFL7‐expressing tumors (right; 70 days (control) vs. 42.5 days (hE7) vs. 40 days (mE7); n = 8; log‐rank test).EmiR‐126 KO did not affect overall survival of GL261 tumor‐bearing mice (n = 8).FEGFL7 KO prolonged overall survival of GL261 tumor‐bearing mice as compared to wild‐type (WT) littermates (44 days in KO vs. 35.5 days in WT; n = 8 each; log‐rank test).GResidual EGFL7 expression in BTPC11 glioma cells was reduced by a lentivirus‐based approach. Knockdown of EGFL7 (shE7_1 or shE7_2) prolonged the median survival time of glioma‐bearing mice (68 days or 69 days) as compared to scrambled control (shScr; 56 days; n = 6; log‐rank test).HThe blood vessel‐specific and miR‐126‐independent KO of EGFL7 in EGFL7fl/fl;Cdh5‐CreERT2 mice prolonged the overall survival of GL261 tumor‐bearing mice as compared to WT littermates (38 days in KO vs. 33 days in WT; n = 7 for KO; n = 5 for WT; log‐rank test).Data information: All data are presented as mean ± SEM. Scale bars represent 5 mm.
Nevenka Dudvarski Stanković et al. EMBO Mol Med. 2018;10:e8420
© as stated in the article, figure or figure legend